Home

Jennifer K. Simpson

CIK 1545253 · President and CEO · last filed 2024-10-03

Jennifer K. Simpson is a President and CEO who has filed 29 SEC Form 4 insider transactions across 4 companies since 2012. Across all open-market trades the lifetime net is +$20.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $412.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$412.3K

Companies

4

Total Filings

29

Lifetime Open-Market Net

$20.4K

Filer Profile

Reported Address
C/O DELCATH SYSTEMS, INC.
810 SEVENTH AVENUE, SUITE 3505
NEW YORK, NY 10019
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Panbela Therapeutics, Inc. (PBLA) Delisted President and CEO 13 $0.01 $0 $0 4 2023-03-29
EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Director — $2.14 — $0 5 2023-03-09
Panbela Therapeutics, Inc. (SNBP) Delisted President and CEO 3,424 — — $2.7K 2 2020-09-14
DCTH President and CEO 25,021 $16.48 $412.3K $17.7K 13 2020-05-08

Recent Filings

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-10-03 — Grant (A) — $0
2024-01-29 — Grant (A) — $0
2023-03-29 Panbela Therapeutics, Inc. (PBLA) Delisted Grant (A) — $0 EDGAR
2023-03-09 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Grant (A) — $0 EDGAR
2023-02-01 Panbela Therapeutics, Inc. (PBLA) Delisted Buy (P) +4,444 $0 EDGAR
2022-03-02 EAGLE PHARMACEUTICALS, INC. (EGRX) Delisted Grant (A) — $0 EDGAR
2022-01-11 — Grant (A) — $0
2021-12-17 — Grant (A) +25,000 $0
2021-09-15 Panbela Therapeutics, Inc. (PBLA) Delisted Grant (A) — $0 EDGAR
2021-04-01 Panbela Therapeutics, Inc. (PBLA) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 29
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.